ZCCHC17

Across TCGA pan-cancer cohorts, ZCCHC17 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of ZCCHC17’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where ZCCHC17 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types ZCCHC17 is over-expressed in tumor, although a few such as PDAC show the opposite, repressed pattern.

HNSC, LSCC, and LUAD are the cancer types where ZCCHC17 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ZCCHC17 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	All	+0.250	<.001	10	view →
LSCC	Male	All	+0.480	<.001	9	view →
LUAD	Male	II,III,IV	+0.440	<.001	9	view →
PDAC	Male	All	−0.953	<.001	8	view →
OV	All	All	+0.212	.041	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

ZCCHC17–HNSC

Open the HNSC breakdown →